News

BPC-157 UK: The Researcher's Buyer Guide (Purity, COA & Pricing 2026)
Sourcing BPC-157 in the UK for research? An honest guide covering what it actually is, what the science shows, the UK legal position, fair 2026 pricing, and how to read a COA to verify what you're buying. Read more...
Retatrutide Phase 3 TRIUMPH Results: What the 2026 Data Shows
Eli Lilly's TRIUMPH Phase 3 programme has reported: 28.3% mean weight loss at 80 weeks, 45.3% of participants losing 30%+, and HbA1c reductions of up to 1.94% in the T2D arm. Here's what the data shows for researchers. Read more...
Retatrutide (GLP-1/GIP/Glucagon Triple Agonist): What Researchers Need to Know
Retatrutide (GLP-1/GIP/Glucagon Triple Agonist)What Researchers Need to Know A review of mechanism, Phase 2 clinical data, and laboratory research considerations for RETAKLIK ⚗️ For laboratory and research use only. All materials supplied by Eurovits are strictly for scientific research purposes and are not intended for human or veterinary use. Introduction Among the most closely watched compounds in metabolic research today, retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — represents a significant step forward from earlier dual-agonist peptides. At Eurovits, we supply RETAKLIK (Retatrutide) as a... Read more...
Retatrutide Research Update: What the Latest Studies Reveal About This Triple Receptor Agonist
An overview of the latest published research on Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, including key Phase 2 trial findings and ongoing research directions. Read more...